Multiple-purpose immunotherapy for cancer.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.biopha.2015.10.020PMID 26653546
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinically feasible approaches to potentiating cancer cell-based immunotherapies

  2015cited by this paper
• Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?

  2014cited by this paper
• TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects

  2014cited by this paper
• Innate and adaptive immune cells in the tumor microenvironment

  2013cited by this paper
• Rational combinations of immunotherapeutics that target discrete pathways

  2013cited by this paper
• Therapeutic cancer vaccines: past, present, and future.

  2013cited by this paper
• Cancer-testis antigens: the current status on antigen regulation and potential clinical use.

  2012cited by this paper
• Immunotherapy: a useful strategy to help combat multidrug resistance.

  2012cited by this paper
• TLR based therapeutics.

  2011cited by this paper
• Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines

  2011cited by this paper
• Beyond Cancer Vaccines: A Reason for Future Optimism With Immunomodulatory Therapy

  2011cited by this paper
• About human tumor antigens to be used in immunotherapy.

  2008cited by this paper
• -galactosylceramide leads to potent and long-lived T cell – mediated immunity via dendritic cells

  2007cited by this paper
• Tumour markers: An overview

  2007cited by this paper
• Xenovaccinotherapy for colorectal cancer.

  2007cited by this paper
• Xenovaccinotherapy for melanoma.

  2006cited by this paper
• Uric Acid Promotes Tumor Immune Rejection

  2004cited by this paper
• Immunotherapeutic potential of whole tumour cells

  2002cited by this paper
• Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines.

  2001cited by this paper
• Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

  2001cited by this paper
• Consequences of cell death: exposure to necrotic tumor cells

  2000cited by this paper
• Consequences of Cell Death

  2000cited by this paper
• Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.

  1998cited by this paper
• gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

  1998cited by this paper
• Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes: a major obstacle for xenotransplantation in humans.

  1993cited by this paper
• A unique natural human IgG antibody with anti-alpha-galactosyl specificity

  1984cited by this paper

• Xenogeneic Testicular Cell Vaccination Induces Long-Term Anti-Cancer Immunity in Mice

  2025influential citation
• Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour Immunostimulation

  2025cites this paper
• Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy

  2025cites this paper
• Molecularly Targeted Therapies In Breast Cancer: A Traditional Review

  2024cites this paper
• Inflammation Control and Immunotherapeutic Strategies in Comprehensive Cancer Treatment

  2023cites this paper
• Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects

  2022cites this paper
• The new progress in cancer immunotherapy

  2022cites this paper
• Therapeutic Approaches to Employ Monoclonal Antibody for Cancer Treatment

  2021cites this paper
• Antitumor and immunoregulatory activities of a novel polysaccharide from Astragalus membranaceus on S180 tumor-bearing mice.

  2021cites this paper
• Different Mechanism Involvement in the Formation of Colorectal Cancer; Mega Review

  2021cites this paper
• Clinically feasible and prospective immunotherapeutic interventions in multidirectional comprehensive treatment of cancer

  2020cites this paper
• Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies

  2020cites this paper
• Promising approaches in cancer immunotherapy.

  2019cites this paper
• Extracorporeal Immunotherapy Methods in the Treatment of Malignant Neoplasms

  2019cites this paper
• Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion article

  2018cites this paper
• Monoclonal antibodies in cancer immunotherapy

  2018cites this paper
• Un néolymphocyte T pour une thérapie médicamenteuse de demain : « espoir ou réalité »

  2017cites this paper
• Human DKK1 and human HSP70 fusion DNA vaccine induces an effective anti-tumor efficacy in murine multiple myeloma

  2017cites this paper
• Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage‐colony stimulating factor and interleukin‐2 surface modified MB49 bladder cancer stem cells vaccine

  2017cites this paper
• STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC

  2017cites this paper
• Xenogeneic cell-based vaccine therapy for colorectal cancer: Safety, association of clinical effects with vaccine-induced immune responses.

  2016cites this paper